Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$202.14 USD

202.14
2,303,503

+0.46 (0.23%)

Updated Nov 6, 2024 01:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - May 08, 2020

by Zacks Equity Research

Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - May 08, 2020

by Zacks Equity Research

The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Signs That Your Trading Will Ruin Your Retirement - May 08, 2020

by Zacks Equity Research

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

Powerful Proof Anyone Can Invest for an Early Retirement - May 05, 2020

by Zacks Equity Research

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

ImmunoGen (IMGN) Q1 Earnings and Sales Miss, Shares Down

by Zacks Equity Research

ImmunoGen (IMGN) reports dismal first-quarter results.

AbbVie's (ABBV) Q1 Earnings and Sales Surpass Estimates

by Zacks Equity Research

AbbVie (ABBV) beats on earnings and revenues in the first quarter of 2020. Shares up in pre-market trading.

Amgen (AMGN) Q1 Earnings Top, to Study Otezla for Coronavirus

by Zacks Equity Research

Amgen (AMGN) beats estimates for both earnings and sales. It maintains its previously-issued financial guidance for 2020.

Earnings Data Deluge

by Zacks Equity Research

Earnings Data Deluge.

Mark Vickery headshot

Quarterly Earnings Beats for Exxon, Clorox, AbbVie & More

by Mark Vickery

Where we find our good news this hour is in quarterly earnings season, where these five big-name companies all outperformed expectations.

AbbVie (ABBV) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

AbbVie (ABBV) delivered earnings and revenue surprises of 6.61% and 2.18%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Allergan (AGN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Allergan's (AGN) first-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products

    The Extreme Risks of Trading Your Own Retirement Assets - April 30, 2020

    by Zacks Equity Research

    Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

    Imbruvica to Offset Humira Woes in AbbVie (ABBV) Q1 Earnings?

    by Zacks Equity Research

    AbbVie's (ABBV) Q1 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs are likely to have witnessed strong growth.

    AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?

    by Zacks Equity Research

    AbbVie's (ABBV) Q1 top line is likely to have been impacted by biosimilar competition for Humira in international markets. However, oncology drugs may have demonstrated strong growth.

    Want To Retire Early? Learn the Intelligent Investing Secret - April 27, 2020

    by Zacks Equity Research

    Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.

    AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

    by Zacks Equity Research

    AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Kinjel Shah headshot

    Pharma Stock Roundup: Q1 Earnings of LLY, Coronavirus Update from PFE, NVS, AZN

    by Kinjel Shah

    Eli Lilly (LLY) announces Q1 results. Pfizer (PFE) and Novartis (NVS) provide update on their studies/plans to make coronavirus treatments or vaccines.

    AbbVie (ABBV) Gains But Lags Market: What You Should Know

    by Zacks Equity Research

    AbbVie (ABBV) closed at $81.47 in the latest trading session, marking a +1.38% move from the prior day.

    Sweta Killa headshot

    Healthcare ETFs Looks Strong Ahead of Q1 Earnings

    by Sweta Killa

    The healthcare sector has been on a tear driven by potential vaccines and treatments for COVID-19.

    Biogen (BIIB) Stock Down Despite Q1 Earnings & Sales Beat

    by Zacks Equity Research

    Biogen (BIIB) beats estimates for both earnings and sales in the first quarter. Stock declines.

    AbbVie Gets FDA Nod for Imbruvica+Rituxan in First-Line CLL

    by Zacks Equity Research

    AbbVie's (ABBV) regulatory application seeking label expansion of Imbruvica as a first-line treatment for chronic lymphocytic leukemia in combination with Roche's Rituxan gets approval from the FDA.

    Can Lilly (LLY) Deliver a Beat in Coronavirus-Hit Q1 Earnings?

    by Zacks Equity Research

    Investor focus is likely to be on the impact of the coronavirus outbreak on Lilly's (LLY) performance when it reports first-quarter results.

    Sheraz Mian headshot

    Q1 Earnings Scorecard and Analyst Reports for Exxon, Oracle & Eli Lilly

    by Sheraz Mian

    In addition to the Q1 earnings scorecard, today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), Oracle (ORCL) and Eli Lilly (LLY).

    Powerful Proof Anyone Can Invest for an Early Retirement - April 17, 2020

    by Zacks Equity Research

    Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.